 Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations Represents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamous non-small cell lung cancer and mesothelioma WOODCLIFF LAKE, N.J., Dec. ... The post Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY in Combination with Pembrolizumab and P... 